Comparative Pharmacology
Head-to-head clinical analysis: ALVESCO versus PULMICORT RESPULES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALVESCO versus PULMICORT RESPULES.
ALVESCO vs PULMICORT RESPULES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciclesonide is a prodrug that is converted to the active metabolite des-ciclesonide, which has anti-inflammatory activity by binding to glucocorticoid receptors, thereby inhibiting inflammatory mediators such as cytokines and leukotrienes.
Glucocorticoid receptor agonist; anti-inflammatory; decreases cytokine production, inhibits inflammatory cell migration, and reduces airway hyperresponsiveness.
Inhalation: 160 mcg twice daily (morning and evening). May be increased to 320 mcg twice daily if inadequate response. Maximum 640 mcg twice daily.
0.5 mg to 1 mg twice daily via nebulization; for maintenance or as replacement therapy, initiate at 0.25 mg twice daily and titrate to clinical response.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours for the systemically absorbed fraction; however, the receptor occupancy half-life is significantly longer due to lipophilic tissue binding, providing therapeutic duration of 12 hours.
Terminal half-life approximately 2-3 hours in children and adults; slightly prolonged in hepatic impairment. Clinical context: supports twice-daily dosing in asthma.
Primarily hepatic metabolism (CYP3A4) to less active metabolites; renal excretion accounts for <10% unchanged; fecal excretion as metabolites ~80%.
Renal: negligible (<5% as unchanged drug). Biliary/fecal: major route, approximately 60-70% as metabolites. Total clearance: 0.5-1.0 L/h.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid